CDK4 and prostate carcinoma: More specifically, we have analyzed patients with prostate cancer under treatment with an androgen receptor targeted agent [10], ovarian cancer receiving treatment with PARP inhibitors [11] and breast cancer patients under treatment with CDK4/6 inhibitors [12].